Mannitol Injection 25%, USP
Mannitol Injection is a sterile, nonpyrogenic osmotic diuretic solution for intravenous use, indicated for the reduction of intracranial pressure and treatment of cerebral edema, as well as the reduction of elevated intraocular pressure. It is available as a 25% solution (12.5 g/50 mL, 0.25 g/mL) in a single-dose fliptop vial, manufactured by Hospira, Inc.
Key Benefits:
• FDA-approved for reduction of intracranial pressure and treatment of cerebral edema
• FDA-approved for reduction of elevated intraocular pressure
• Osmotic diuretic mechanism induces movement of intracellular water to extracellular and vascular spaces, providing clinically relevant pressure reduction
• Available in a single-dose vial formulation — contains no bacteriostat or antimicrobial agent
• Approved for use in both adult and pediatric populations for the reduction of intracranial and intraocular pressure
Dosage & Administration:
For reduction of intracranial pressure and cerebral edema, the recommended dose is 0.25 g/kg administered as an intravenous infusion over at least 30 minutes, repeated every 6 to 8 hours. For reduction of intraocular pressure, the recommended dose is 1.5 to 2 g/kg as a single intravenous infusion over at least 30 minutes, administered 60 to 90 minutes before surgery when used preoperatively. Mannitol Injection is preferably administered through a central venous catheter, and renal, cardiac, and pulmonary status should be evaluated prior to administration.
Why Choose Mannitol Injection 25%, USP?
Mannitol Injection 25%, USP is a high-concentration osmotic diuretic specifically formulated for intravenous administration in a ready-to-use single-dose vial, addressing both intracranial and intraocular pressure indications as described in the prescribing information.
Warnings:
• Serious hypersensitivity reactions, including anaphylaxis, hypotension, dyspnea, cardiac arrest, and death have been reported; stop the infusion immediately if signs or symptoms of a hypersensitivity reaction develop
• Renal complications, including irreversible renal failure, have been reported; patients with pre-existing renal disease or those receiving nephrotoxic drugs are at increased risk and mannitol should be discontinued if renal function worsens
• CNS toxicity, including confusion, lethargy, and coma (some resulting in death), has been reported, particularly in the presence of impaired renal function; discontinue Mannitol Injection if CNS toxicity develops
Disclaimer: This product description was generated by AI and is for informational purposes only. Please refer to the latest package insert for complete information on indications,
contraindications, warnings, and proper use.
